4.6 Article

Validation of the 2019 Expert Consensus Algorithm for the Management of Conduction Disturbances After TAVR

期刊

JACC-CARDIOVASCULAR INTERVENTIONS
卷 14, 期 9, 页码 981-991

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jcin.2021.03.010

关键词

conduction disturbances; ECG algorithm; pacemaker implantation; transcatheter aortic valve replacement

资金

  1. Edwards Lifesciences
  2. Medtronic
  3. Abbott Vascular
  4. Boston Scientific
  5. Abbott
  6. Biotronik
  7. Medis
  8. Sanofi
  9. Regeneron
  10. Amgen
  11. Bristol Myers Squibb
  12. Bayer
  13. Cardinal Health
  14. Cardiovalve
  15. CSL Behring
  16. Daiichi-Sankyo
  17. Johnson Johnson
  18. Querbet
  19. Polares
  20. Terumo
  21. Sinomed
  22. Abiomed
  23. MedAlliance
  24. Novartis
  25. VWave
  26. Xeltis

向作者/读者索取更多资源

OBJECTIVES The aim of this study was to validate the 2019 consensus algorithm in a large cohort of contemporary transcatheter aortic valve replacement (TAVR) patients. BACKGROUND The optimal management of patients with atrioventricular conduction disturbances after TAVR is unknown. Guidance was consolidated in an expert consensus algorithm in 2019. METHODS In a retrospective analysis of a prospective registry, patients were classified according to the 2019 consensus algorithm as eligible for early discharge (day 1 or 2 after TAVR), higher risk for high-degree atrioventricular block (HAVB) or complete heart block (CHB) or in need for a permanent pacemaker (PPM). The primary endpoint was the incidence of PPM implantation for HAVB or CHB within 30 days after TAVR. Patients with prior PPM or implantable cardioverter-defibrillator implantation, valve-in-valve procedures, or incomplete electrocardiographic data were excluded. RESULTS Among 1,439 patients undergoing TAVR between January 2014 and December 2019, the 2019 consensus algorithm classified 73% as eligible for early discharge, 21% as at higher risk for HAVB or CHB, and 6% as in need of PPM. PPM implantation for HAVB or CHB occurred in 234 patients (16%) within 30 days after TAVR. The incidence of PPM implantation was 2.7% in the early discharge group, 41% in the group with higher risk for HAVB or CHB, and 100% in the PPM group. CONCLUSIONS The 2019 consensus algorithm safely identifies patients with no need for PPM implantation. This strategy allows more uniform management of TAVR patients and facilitates early discharge of low-risk patients without prolonged monitoring in 3 of 4 patients. However, the algorithm is less precise in the identification of high-risk patients. (C) 2021 by the American College of Cardiology Foundation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据